Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Castanospermine SCHEMBL29356587 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL10471084 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL30094437 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL31666834 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL23845877 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL2434193 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL23689596 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL4645261 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL764545 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 | |
| Castanospermine SCHEMBL13666292 | 1.00 | GAA (1.00) | GAAMEN1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346760-A1 | AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-8242136-B2 | Use of glucosidase inhibitors for therapy of mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-08-14 | — | — | US | disclosed |
| US-8242136-B2 | Use of glucosidase inhibitors for therapy of mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-08-14 | — | — | US | disclosed |
| US-20110269795-A1 | USE OF GLUCOSIDASE INHIBITORS FOR THERAPY OF MUCOVISIDOSIS | UNIVERSITE DE POITIERS (FR) | 2011-11-03 | — | — | US | disclosed |
| US-20110269795-A1 | USE OF GLUCOSIDASE INHIBITORS FOR THERAPY OF MUCOVISIDOSIS | UNIVERSITE DE POITIERS (FR) | 2011-11-03 | — | — | US | disclosed |
| US-7973054-B2 | Use of glucosidase inhibitors for therapy of mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2011-07-05 | — | — | US | disclosed |
| US-7973054-B2 | Use of glucosidase inhibitors for therapy of mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2011-07-05 | — | — | US | disclosed |
| US-20070213357-A1 | Use of Glucosidase Inhibitors for Therapy of Mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-09-13 | — | — | US | disclosed |
| US-20070213357-A1 | Use of Glucosidase Inhibitors for Therapy of Mucovisidosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346760-A1 | AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB | SI, UGDH, UGGT1 | GAA 101/4885MEN1 4780/4885CYP1A2 2201/4885 |
| US-20110269795-A1 | USE OF GLUCOSIDASE INHIBITORS FOR THERAPY OF MUCOVISIDOSIS | MAN2B1, GAA, MAN2A1 | GAA 2/4885MEN1 808/4885CYP1A2 281/4885 |
| US-20070213357-A1 | Use of Glucosidase Inhibitors for Therapy of Mucovisidosis | MAN2B1, GAA, MAN2A1 | GAA 2/4885MEN1 990/4885CYP1A2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.